Dissociation of renal and respiratory effects of acetazolamide in the critically ill.

The effects of acetazolamide on renal and erythrocyte carbonic anhydrase were studied in 12 critically ill patients. In the first part of the investigation (n = 6) we examined the renal effects of increasing doses of acetazolamide. The maximal renal excretion of water and bicarbonate was achieved with acetazolamide 2.5-5 mg kg-1 i.v. In the second part (n = 6), the associated respiratory effects of the effective renal dose of acetazolamide 5 mg kg-1 were evaluated. We found a statistically significant 4% decrease in pulmonary carbon dioxide excretion in the 10-min sampling period immediately following the administration of acetazolamide, but thereafter carbon dioxide elimination proceeded at a normal rate. The observed carbon dioxide retention is clinically unimportant, and we recommend acetazolamide as an effective means of eliminating surplus water and bicarbonate in the critically ill.

[1]  P. D.,et al.  Cardiovascular performance and oxyhemoglobin dissociation after acetazolamide in metabolic alkalosis , 2005, Intensive Care Medicine.

[2]  I. Gøthgen,et al.  Oxygen uptake and carbon dioxide elimination after acetazolamide in the critically ill , 2004, Intensive Care Medicine.

[3]  D. Brater,et al.  Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects. , 1983, The Journal of pharmacology and experimental therapeutics.

[4]  P. Berthelsen,et al.  Carbon Dioxide Elimination after Acetazolamide in Patients with Chronic Obstructive Pulmonary Disease and Metabolic Alkalosis , 1983, Acta anaesthesiologica Scandinavica.

[5]  R. Bulger,et al.  Renal carbonic anhydrase. , 1982, The American journal of physiology.

[6]  S. Javaheri,et al.  Compensatory hypoventilation in metabolic alkalosis. , 1982, Chest.

[7]  P. Wistrand.  The importance of carbonic anhydrase B and C for the unloading of CO2 by the human erythrocyte. , 1981, Acta physiologica Scandinavica.

[8]  J. Hodgkin,et al.  Incidence of metabolic alkalemia in hospitalized patients , 1980, Critical care medicine.

[9]  R Fletcher,et al.  Clinical studies of gas exchange during ventilatory support--a method using the Siemens-Elema CO2 analyzer. , 1980, British journal of anaesthesia.

[10]  T. Gallagher.  Metabolic alkalosis complicating weaning from mechanical ventilation. , 1979, Southern medical journal.

[11]  A. Mattocks,et al.  Nonlinear model for acetazolamide. , 1979, Journal of pharmaceutical sciences.

[12]  P. Miller,et al.  Acute metabolic alkalosis perpetuating hypercarbia. A role for acetazolamide in chronic obstructive pulmonary disease. , 1977, JAMA.

[13]  E. Phillipson,et al.  Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease. , 1977, Canadian Medical Association journal.

[14]  T. Maren,et al.  Inhibition by anions of human red cell carbonic anhydrase B: physiological and biochemical implications. , 1976, Science.

[15]  L. P. Leblanc,et al.  Severe Alkalosis in Critically Ill Surgical Patients , 1972 .

[16]  R. Luke,et al.  Ventilatory failure due to metabolic alkalosis. , 1972, Chest.

[17]  T. Maren,et al.  Respiration during chronic inhibition of renal carbonic anhydrase: further observations on pharmacology of 2-benzenesulfonamido-1,3, 4-thiadiazole-5-sulfonamide (CL 11,366), acetazolamide and methazolamide. , 1966, The Journal of pharmacology and experimental therapeutics.